Roche earns FDA approval for a combined flu/COVID diagnostic, I-Mab signs with Abbvie for $2 billion, PPD partners to treat lupus, and BioNTech/Pfizer add more COVID candidates while Moderna adds bad press.

Sponsors
www.thescopemethod.com

Story References
https://www.businesswire.com/news/home/20200903005517/en/PPD-Lupus-Therapeutics-Collaborate-Support-Lupus-Clinical
https://www.fiercebiotech.com/biotech/pfizer-biontech-quietly-usher-a-5th-covid-19-jab-into-clinic-analyst
https://www.npr.org/2020/09/04/908305074/bad-optics-or-something-more-moderna-executives-stock-sales-raise-concerns
https://www.roche.com/media/releases/med-cor-2020-09-04.htm
https://www.usnews.com/news/us/articles/2020-09-02/us-nih-awards-nine-companies-129-million-to-scale-up-covid-19-testing

Music by Luke Goodson
www.soundcloud.com/lukegoodson

 
The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.